Because the medicine enters the fatty tissue directly, it bypasses the digestive system and the livers first-pass metabolism
[1] Dose-escalation studies, such as a 12-week trial on gradual titration, revealed that beginning at lower doses (e.g., 4 mg) and slowly increasing to therapeutic levels significantly reduced the incidence of nausea, vomiting, and diarrhoea
The medical supervision gave me confidence in the treatment plan, and it helped me stick to healthier habits over time
Your maintenance cost can climb with dose and plan length
The dual agonist approach: tirzepatide Tirzepatide activates two receptors simultaneously
Ex vivo studies were also conducted on human subcutaneous adipose tissue arterioles and endothelial cells